trialsTrialRecruiting

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

A phase 3 trial of Lerociclib run by Genor Biopharma Co., Ltd., now recruiting.

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT05851014 by Genor Biopharma Co., Ltd., with 350 participants planned, started 2022-01-14. Conditions listed: Breast Cancer. No results are recorded here; the registry entry is the source.

Setting

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

Phase

Phase 3

Sponsor

Genor Biopharma Co., Ltd.

Registry

NCT05851014

Started

2022-01-14

Enrolled

350 enrolled

Connected

3top

cancers

HR-positive / HER2-negative breast cancer

technologies

Small-molecule kinase inhibitors

drugs

Phase 3Oral CDK4/6 inhibitor

Lerociclib

Evidence strength43/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 3+30
350 enrolled+13
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT05851014

Data

JSON ·

Follow this page

Follow by feed

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers

HR-positive / HER2-negative breast cancer

Technologies

Small-molecule kinase inhibitors

Products

Lerociclib

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

trialsTrialRecruiting

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

A phase 3 trial of Lerociclib run by Genor Biopharma Co., Ltd., now recruiting.

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT05851014 by Genor Biopharma Co., Ltd., with 350 participants planned, started 2022-01-14. Conditions listed: Breast Cancer. No results are recorded here; the registry entry is the source.

Setting

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

Phase

Phase 3

Sponsor

Genor Biopharma Co., Ltd.

Registry

NCT05851014

Started

2022-01-14

Enrolled

350 enrolled

Connected

3top

cancers

HR-positive / HER2-negative breast cancer

technologies

Small-molecule kinase inhibitors

drugs

Phase 3Oral CDK4/6 inhibitor

Lerociclib

Evidence strength43/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 3+30
350 enrolled+13
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT05851014

Data

JSON ·

Follow this page

Follow by feed

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers

HR-positive / HER2-negative breast cancer

Technologies

Small-molecule kinase inhibitors

Products

Lerociclib

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Overview

Connected

cancers

technologies

drugs

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Overview

Connected

cancers

technologies

drugs